AVAMYS 27.5 micrograms/spray nasal spray suspension

  • Name:

    AVAMYS 27.5 micrograms/spray nasal spray suspension

  • Company:
    info
  • Active Ingredients:

    Fluticasone furoate

  • Legal Category:

    Product subject to medical prescription which may be renewed (B)

Patient Information Leaflet Patient Information Leaflet last updated on medicines.ie: 17/12/18

files-icon(Click to Download)
Summary of Product Characteristics last updated on medicines.ie: 17/12/2018

Click on this link to Download PDF directly

GlaxoSmithKline (Ireland) Ltd

GlaxoSmithKline (Ireland) Ltd

Company Products

Medicine NameActive Ingredients
Medicine Name Amoxil Paediatric Suspension Active Ingredients Amoxicillin trihydrate
Medicine Name Amoxil Vial for Injection 500mg Active Ingredients Amoxicillin sodium
Medicine Name ANORO ELLIPTA 55 micrograms/22 micrograms inhalation powder, pre-dispensed Active Ingredients Umeclidinium bromide, Vilanterol trifenatate
Medicine Name Augmentin 250 mg/125 mg film-coated tablets Active Ingredients Amoxicillin trihydrate, Potassium clavulanate
Medicine Name Augmentin 500mg/125mg Film-coated Tablets Active Ingredients Amoxicillin trihydrate, Potassium clavulanate
Medicine Name Augmentin 875/125mg Film Coated tablets Active Ingredients Amoxicillin trihydrate, Clavulanic Acid
Medicine Name Augmentin Duo Mixed Fruit 400 mg/57 mg /5 ml Powder for Oral Suspension Active Ingredients Amoxicillin trihydrate, Clavulanic Acid
Medicine Name Augmentin DUO Suspension 400/57mg Active Ingredients Amoxicillin trihydrate, Potassium clavulanate
Medicine Name Augmentin Intravenous 1.2g Active Ingredients Amoxicillin sodium, Potassium clavulanate
Medicine Name Augmentin Paediatric 125mg/31.25mg per 5ml Powder for Oral Suspension Active Ingredients Amoxicillin trihydrate, Potassium clavulanate
Medicine Name AVAMYS 27.5 micrograms/spray nasal spray suspension Active Ingredients Fluticasone furoate
Medicine Name Avodart Soft Capsules 0.5mg Active Ingredients Dutasteride
Medicine Name Babyhaler Active Ingredients No Active Ingredients
Medicine Name Bactroban Nasal Ointment Active Ingredients Mupirocin calcium
Medicine Name Bactroban Ointment Active Ingredients Mupirocin
Medicine Name Becotide Evohaler 100 Active Ingredients Beclometasone Dipropionate
Medicine Name Becotide Evohaler 250 Active Ingredients Beclometasone Dipropionate
Medicine Name Becotide Evohaler 50 Active Ingredients Beclometasone Dipropionate
Medicine Name Benlysta 120 mg and 400 mg powder for concentrate for solution for infusion Active Ingredients Belimumab
Medicine Name Betnovate C 0.1% / 3% w/w Cream Active Ingredients Betamethasone Valerate, Clioquinol
Medicine Name Betnovate Cream 0.1% w/w Active Ingredients Betamethasone Valerate
Medicine Name Betnovate Ointment 0.1% w/w Active Ingredients Betamethasone Valerate
Medicine Name Betnovate RD Cream Active Ingredients Betamethasone Valerate
Medicine Name Betnovate RD Ointment Active Ingredients Betamethasone Valerate
Medicine Name Betnovate Scalp Application 0.1% w/v Cutaneous Solution Active Ingredients Betamethasone Valerate
1 - 0 of 136 items.Total: Infinity pages

When a pharmaceutical company changes any document, a new version is published on medicines.ie. For each version, we show the dates it was published on medicines.ie and the reasons for change.

Updated on 17 December 2018 PIL

Reasons for updating

  • Change to section 4 - how to report a side effect
  • Change to section 6 - marketing authorisation holder
  • Change to section 6 - date of revision

Updated on 17 December 2018 SmPC

Reasons for updating

  • Change to Section 4.8 – Undesirable effects - how to report a side effect
  • Change to section 7 - Marketing authorisation holder
  • Change to section 10 - Date of revision of the text

Legal category: Product subject to medical prescription which may be renewed (B)

Free text change information supplied by the pharmaceutical company

Section 4.8: Splitting of pack to include just specific UK reporting details due to Brexit preparations
Section 7: Change of MAH address

Updated on 12 July 2017 SmPC

Reasons for updating

  • New SmPC for new product

Legal category: Product subject to medical prescription which may be renewed (B)

Updated on 12 July 2017 SmPC

Reasons for updating

  • Change to section 4.4 - Special warnings and precautions for use
  • Change to section 4.8 - Undesirable effects
  • Change to section 10 - Date of revision of the text

Legal category: Product subject to medical prescription which may be renewed (B)

Free text change information supplied by the pharmaceutical company

Update to section 4.4 and 4.8 to include warnings and adverse event related to blurred vision following PRAC recommendation.

Updated on 11 July 2017 PIL

Reasons for updating

  • New PIL for new product

Updated on 11 July 2017 PIL

Reasons for updating

  • Change to section 2 - use in children and adolescents
  • Change to section 4 - possible side effects
  • Change to section 6 - date of revision

Updated on 7 June 2017 SmPC

Reasons for updating

  • Change to section 4.5 - Interaction with other medicinal products and other forms of interaction
  • Change to section 10 - Date of revision of the text

Legal category: Product subject to medical prescription which may be renewed (B)

Free text change information supplied by the pharmaceutical company

SmPC section 4.5: text updated to incorporate PRAC recommendations for the interaction of corticosteroids with cobicistat into the Avamys labelling. Approved heading text corrected and a redundant cross reference to SmPC 4.4 removed.

Updated on 7 June 2017 PIL

Reasons for updating

  • Change to section 2 - interactions with other medicines, food or drink
  • Change to section 6 - date of revision

Updated on 4 January 2016 SmPC

Reasons for updating

  • Change to section 4.2 - Posology and method of administration
  • Change to section 4.4 - Special warnings and precautions for use
  • Change to section 10 - Date of revision of the text

Legal category: Product subject to medical prescription which may be renewed (B)

Free text change information supplied by the pharmaceutical company

Section 4.2 – removal of hepatic impairment dosing information
Section 4.4 – removal of hepatic impairment warning information
Section 10 – date of revision updated

Updated on 24 December 2015 PIL

Reasons for updating

  • Change to warnings or special precautions for use
  • Change to further information section
  • Change to date of revision

Updated on 4 November 2015 SmPC

Reasons for updating

  • Change to section 4.8 - Undesirable effects
  • Change to Section 4.8 – Undesirable effects - how to report a side effect
  • Change to section 10 - Date of revision of the text

Legal category: Product subject to medical prescription which may be renewed (B)

Free text change information supplied by the pharmaceutical company

Section 4.8 – addition of Nasal septum perforation to adverse event table with a frequency classification of very rare

Updated on 3 November 2015 PIL

Reasons for updating

  • Change to side-effects
  • Change to date of revision

Updated on 10 April 2015 SmPC

Reasons for updating

  • Change to section 4.2 - Posology and method of administration
  • Change to section 4.4 - Special warnings and precautions for use
  • Change to section 4.5 - Interaction with other medicinal products and other forms of interaction
  • Change to Section 4.8 – Undesirable effects - how to report a side effect
  • Change to section 5.2 - Pharmacokinetic properties
  • Change to section 10 - Date of revision of the text
  • Correction of spelling/typing errors

Legal category: Product subject to medical prescription which may be renewed (B)

Free text change information supplied by the pharmaceutical company

Description of change to SPC:

Section 4.2 – amendment to hepatic impairment dose recommendations

Section 4.4 – typographical change

Section 4.5 – typographical change

Section 4.8 – typographical change

Section 5.2 – amendment to hepatic impairment information

Updated on 9 January 2014 PIL

Reasons for updating

  • Change to side-effects

Updated on 9 January 2014 SmPC

Reasons for updating

  • Change to section 4.8 - Undesirable effects
  • Change to section 5.1 - Pharmacodynamic properties
  • Change to section 6.1 - List of excipients

Legal category: Product subject to medical prescription which may be renewed (B)

Free text change information supplied by the pharmaceutical company

Change to:

 

 

Section 4.8 - Undesirable effects,
Section 5.1 - Pharmacodynamic properties,
Section 6.1 - List of excipients

 

Updated on 9 July 2013 SmPC

Reasons for updating

  • Change to section 6.5 - Nature and contents of container

Legal category: Product subject to medical prescription which may be renewed (B)

Free text change information supplied by the pharmaceutical company

Change to:

Section 6.5 with the addition of the new Type III bottle

Updated on 17 May 2013 SmPC

Reasons for updating

  • Change to section 7 - Marketing authorisation holder

Legal category: Product subject to medical prescription which may be renewed (B)

Free text change information supplied by the pharmaceutical company

Change to:

Section 7 - MARKETING AUTHORISATION HOLDER

Updated on 18 February 2013 SmPC

Reasons for updating

  • Change to section 1 - Name of medicinal product
  • Change to section 2 - Qualitative and quantitative composition
  • Change to section 4.1 - Therapeutic indications
  • Change to section 4.2 - Posology and method of administration
  • Change to section 4.3 - Contraindications
  • Change to section 4.4 - Special warnings and precautions for use
  • Change to section 4.5 - Interaction with other medicinal products and other forms of interaction
  • Change to section 4.6 - Pregnancy and lactation
  • Change to section 4.7 - Effects on ability to drive and use machines
  • Change to section 5.1 - Pharmacodynamic properties
  • Change to section 5.2 - Pharmacokinetic properties
  • Change to section 6.4 - Special precautions for storage
  • Change to section 6.5 - Nature and contents of container

Legal category: Product subject to medical prescription which may be renewed (B)

Free text change information supplied by the pharmaceutical company

AVAMYS 27.5 micrograms/spray nasal spray suspension

 

Summary of Changes further to the approval on 17/12/2012 of the MA Renewal (EMEA/H/C/770/R/0014) with updates to the SPC, PIL and Labelling regarding:

·             Warnings & Precaution, Adverse Reactions, Clinical Studies and GPL: Possible side effects – Details: Addition of findings from a one-year paediatric growth study.

·             Warnings & Precaution and Clinical Studies – Details: Addition of findings from a two-year ocular safety study in adults/adolescents.

 

 

SPC UPDATES

 

Minor editorial updates to sections 1, 2, 4.2, 4.3, 4.9, 5.1 and 5.2

 

4.1     Therapeutic indications

Indication updated to specify minimum age of 6 years (previously 11 years), i.e. to read:

Avamys is indicated in adults, adolescents and children (6 years and over)

 

4.2       Posology and method of administration

Section updated and rearranged under two sub-headings ‘Posology’ and ‘Method of administration’.

 

Under the sub-headings ‘Posology/Children under 6 years of age’, revised the wording to read:

The safety and efficacy of Avamys in children under the age of 6 years has not been established. Currently available data are described in section 5.1 and 5.2 but no recommendation on a posology can be made.

 

Under the sub-headings ‘Posology/Hepatic Impairment’ added the warning:

Caution should be exercised when dosing patients with severe hepatic impairment as patients with hepatic impairment may be more at risk of systemic adverse reactions associated with corticosteroids.

 

4.4       Special warnings and precautions for use

The following statements were deleted:

As with other intranasal corticosteroids, physicians should be alert to potential systemic steroid effects including ocular changes (see Pharmacodynamic properties).

 

Avamys contains benzalkonium chloride. It may cause irritation of the nasal mucosa.

 

The following new sub-headings were added ‘Systemic corticosteroid effects’, ‘Eye disorders’, ‘Growth retardation’, ‘Patients on ritonavir’, and ‘Patients with hepatic impairment’, and the relevant paragraphs have been moved under these.

 

4.5       Interaction with other medicinal products and other forms of interaction

Added the sub-heading ‘Interaction with CYP3A4 inhibitors’; no changes to text.

 

4.6       Fertility, pregnancy and lactation

Section updated and rearranged under three sub-headings ‘Pregnancy’, ‘Breast-feeding’ and ‘Fertility’, with the following text added under ‘Fertility’:

There are no fertility data in humans.

 

4.7       Effects on ability to drive and use machines

Updated the statement to read:

Avamys has no or negligible influence on the ability to drive and use machines.

 

5.1       Pharmacodynamic properties

Added the description ‘nasal preparations’ to the Pharmacotherapeutic group

 

6.4       Special precautions for storage

Added the following instructions:

Store upright.

Always keep the cap on.

 

6.5       Nature and contents of container

Updated the description to remove details on the plastic device, and added the description of the volume of the product, to read:

14.2 ml suspension in a Type I amber bottle (glass) fitted with a metering spray pump.

Updated on 13 February 2013 PIL

Reasons for updating

  • Change to, or new use for medicine
  • Change to warnings or special precautions for use
  • Change to side-effects

Updated on 24 September 2012 SmPC

Reasons for updating

  • Change to section 4.4 - Special warnings and precautions for use
  • Change to section 4.8 - Undesirable effects
  • Change to section 5.1 - Pharmacodynamic properties

Legal category: Product subject to medical prescription which may be renewed (B)

Free text change information supplied by the pharmaceutical company

SPC UPDATES

 

4.4       Special warnings and precautions for use

The following warning was added regarding a reduction in growth rate in children and the potential systemic steroid effects including ocular changes

A reduction in growth velocity has been observed in children treated with fluticasone furoate 110 micrograms daily for one year (see Undesirable Effects and Pharmacodynamic properties). Therefore, children should be maintained on the lowest possible efficacious dose which delivers adequate symptom control (see Posology and method of administration). As with other intranasal corticosteroids, physicians should be alert to potential systemic steroid effects including ocular changes (see Pharmacodynamic properties).

 

4.8       Undesirable effects

Added the following undesirable effects with the frequency ‘not known’:

Transient ocular changes

Growth retardation

 

Regarding the undesirable effect ‘Growth retardation’ the following explanatory note was added

In a one-year clinical study assessing growth in pre-pubescent children receiving 110 micrograms of fluticasone furoate once daily, an average treatment difference of -0.27 cm per year in growth velocity was observed compared to placebo (see Clinical experience).

 

 

5.1       Pharmacodynamic properties

Under the subheading ‘Perennial Allergic Rhinitis in adults and adolescents’, the following was added:

In a two-year study designed to assess the ocular safety of fluticasone furoate (110 micrograms once daily intranasal spray), adults and adolescents with perennial allergic rhinitis received either fluticasone furoate (n=367) or placebo (n=181). The primary outcomes [time to increase in posterior subcapsular opacity (³0.3 from baseline in Lens Opacities Classification System, Version III (LOCS III grade)) and time to increase in intraocular pressure (IOP; ³7 mmHg from baseline)] were not statistically significant between the two groups. Increases in posterior subscapsular opacity (³0.3 from baseline) were more frequent in subjects treated with fluticasone furoate 110 micrograms [14 (4%)] versus placebo [4 (2%)] and were transient in nature for ten subjects in the fluticasone furoate group and two subjects in the placebo group. Increases in IOP (³7 mmHg from baseline) were more frequent in subjects treated with fluticasone furoate 110 micrograms: 7 (2%) for fluticasone furoate 110 micrograms once daily and 1 (<1%) for placebo. These events were transient in nature for six subjects in the fluticasone furoate group and one placebo subject. At weeks 52 and 104, 95% of subjects in both treatment groups had posterior subcapsular opacity values within ± 0.1 of baseline values for each eye and, at week 104, ≤1% of subjects in both treatment groups had ³0.3 increase from baseline in posterior subcapsular opacity.  At weeks 52 and 104, the majority of subjects (>95%) had IOP values of within ± 5mmHg of the baseline value.  Increases in posterior subcapsular opacity or IOP were not accompanied by any adverse events of cataracts or glaucoma.

 

Under the subheading ‘Seasonal and perennial allergic rhinitis in children’ replaced the following statement regarding growth rate:

Results from a placebo-controlled knemometry study of fluticasone furoate nasal spray 110 micrograms once daily revealed no clinically relevant effects on short-term lower leg growth rate in children (6 to 11 years).

 

With the following:

A randomised, double-blind, parallel-group, multicenter, one-year placebo-controlled clinical growth study evaluated the effect of fluticasone furoate nasal spray 110 micrograms daily on growth velocity in 474 prepubescent children (5 to 7.5 years of age for girls and 5 to 8.5 years of age for boys) with stadiometry. Mean growth velocity over the 52-week treatment period was lower in the patients receiving fluticasone furoate (5.19 cm/year) compared to placebo (5.46 cm/year). The mean treatment difference was -0.27 cm per year [95% CI -0.48 to -0.06].

 

Updated on 19 September 2012 PIL

Reasons for updating

  • Change to warnings or special precautions for use

Updated on 1 June 2012 SmPC

Reasons for updating

  • Change to section 4.8 - Undesirable effects

Legal category: Product subject to medical prescription which may be renewed (B)

Free text change information supplied by the pharmaceutical company

Change to:

 

 

Section 4.8 - Undesirable effects

 

Updated on 31 May 2012 PIL

Reasons for updating

  • Change to side-effects

Updated on 30 November 2011 SmPC

Reasons for updating

  • Change to section 4.4 - Special warnings and precautions for use
  • Change to section 4.8 - Undesirable effects

Legal category: Product subject to medical prescription which may be renewed (B)

Free text change information supplied by the pharmaceutical company

Revision to Section 4.4 & 4.8

Updated on 8 April 2010 PIL

Reasons for updating

  • Change of manufacturer
  • Change to storage instructions
  • Change to side-effects

Updated on 31 March 2010 PIL

Reasons for updating

  • Change of manufacturer
  • Change to storage instructions
  • Change to side-effects

Updated on 26 March 2010 SmPC

Reasons for updating

  • Change to section 4.8 - Undesirable effects

Legal category: Product subject to medical prescription which may be renewed (B)

Free text change information supplied by the pharmaceutical company

4.8       Undesirable effects

 

Data from large clinical trials were used to determine the frequency of adverse reactions.

The following convention has been used for the classification of frequencies: Very common 1/10; Common 1/100 to <1/10; Uncommon 1/1000 to <1/100; Rare 1/10,000 to <1/1000; Very rare <1/10,000.

 

Immune system disorders

Rare

Hypersensitivity reactions including anaphylaxis, angioedema, rash, and urticaria.

Respiratory, thoracic and mediastinal disorders

Very common

*Epistaxis

Common

Nasal ulceration

 

*Epistaxis was generally mild to moderate in intensity. In adults and adolescents, the incidence of epistaxis was higher in longer-term use (more than 6 weeks) than in short-term use (up to 6 weeks). In paediatric clinical studies of up to 12 weeks duration the incidence of epistaxis was similar between patients receiving fluticasone furoate and patients receiving placebo.

 

Systemic effects of nasal corticosteroids may occur, particularly when prescribed at high doses for prolonged periods.

 

Updated on 20 July 2009 SmPC

Reasons for updating

  • Change to section 4.2 - Posology and method of administration
  • Change to section 4.4 - Special warnings and precautions for use
  • Change to section 4.8 - Undesirable effects

Legal category: Product subject to medical prescription which may be renewed (B)

Free text change information supplied by the pharmaceutical company

SUMMARY OF CHANGES (IN RED) TO

SUMMARY OF PRODUCT CHARACTERISTICS

AVAMYS 27.5 micrograms/spray

nasal spray suspension

 

4.2     Posology and method of administration

 

Avamys nasal spray is for administration by the intranasal route only.

 

For full therapeutic benefit regular, scheduled usage is recommended. Onset of action has been observed as early as 8 hours after initial administration. However, it may take several days of treatment to achieve maximum benefit, and the patient should be informed that their symptoms will improve with continuous regular use (see section 5.1). The duration of treatment should be restricted to the period that corresponds to allergenic exposure.

 

 

Adults and Adolescents (12 years and over)

The recommended starting dose is two spray actuations (27.5 micrograms of fluticasone furoate per spray actuation) in each nostril once daily (total daily dose, 110 micrograms).

 

Once adequate control of symptoms is achieved, dose reduction to one spray actuation in each nostril (total daily dose 55 micrograms) may be effective for maintenance.

 

The dose should be titrated to the lowest dose at which effective control of symptoms is maintained.

 

Children (6 to 11 years of age)

The recommended starting dose is one spray actuation (27.5 micrograms of fluticasone furoate per spray actuation) in each nostril once daily (total daily dose, 55 micrograms).

 

Patients not adequately responding to one spray actuation in each nostril once daily (total daily dose, 55 micrograms) may use two spray actuations in each nostril once daily (total daily dose, 110 micrograms).

Once adequate control of symptoms is achieved, dose reduction to one spray actuation in each nostril once daily (total daily dose, 55 micrograms) is recommended.

 

Children under 6 years of age: The experience in children under the age of 6 years is limited (see section 5.1 and 5.2). Safety and efficacy in this group has not been well established.

 

Elderly Patients: No dose adjustment is required in this population (see section 5.2).

 

Renal Impaired Patients: No dose adjustment is required in this population (see section 5.2).

 

Hepatic Impaired Patients: No dose adjustment is required in mild to moderate hepatic impairment. There are no data in patients with severe hepatic impairment (see section 4.4 and 5.2).

 

The intranasal device should be shaken before use. The device is primed by pressing the mist release button for at least six spray actuations (until a fine mist is seen), whilst holding the device upright. Re-priming (approximately 6 sprays until a fine mist is seen) is only necessary if the cap is left off for 5 days or the intranasal device has not been used for 30 days or more.

The device should be cleaned after each use and the cap replaced.

 

 

 

4.4     Special warnings and precautions for use

 

Avamys undergoes extensive first-pass metabolism, therefore the systemic exposure of intranasal fluticasone furoate in patients with severe liver disease is likely to be increased. This may result in a higher frequency of systemic adverse events (see section 4.2 and 5.2). Caution is advised when treating these patients.

 

Ritonavir

Concomitant administration with ritonavir is not recommended because of the risk of increased systemic exposure of fluticasone furoate (see section 4.5).

 

Systemic effects of nasal corticosteroid may occur, particularly at high doses prescribed for prolonged periods. These effects vary between patients and different corticosteroids (see section 5.2).

 

Treatment with higher than recommended doses of nasal corticosteroids may result in clinically significant adrenal suppression. If there is evidence for higher than recommended doses being used, then additional systemic corticosteroid cover should be considered during periods of stress or elective surgery. Fluticasone furoate 110 micrograms once daily was not associated with hypothalamic-pituitary-adrenal (HPA) axis suppression in adult, adolescent or paediatric subjects. However the dose of intranasal fluticasone furoate should be reduced to the lowest dose at which effective control of the symptoms of rhinitis is maintained. As with all intranasal corticosteroids, the total systemic burden of corticosteroids should be considered whenever other forms of corticosteroid treatment are prescribed concurrently.

 

Growth retardation has been reported in children receiving some nasal corticosteroids at licensed doses. It is recommended that the height of children receiving prolonged treatment with nasal corticosteroids is regularly monitored. If growth is slowed, therapy should be reviewed with the aim of reducing the dose of nasal corticosteroid if possible, to the lowest dose at which effective control of symptoms is maintained. In addition, consideration should be given to referring the patient to a paediatric specialist (see section 5.1).

 

If there is any reason to believe that adrenal function is impaired, care must be taken when transferring patients from systemic steroid treatment to fluticasone furoate.

 

Nasal and inhaled corticosteroids may result in the development of glaucoma and/or cataracts. Therefore close monitoring is warranted in patients with a change in vision or with a history of increased intraocular pressure, glaucoma and/or cataracts.

 

Avamys contains benzalkonium chloride. It may cause irritation of the nasal mucosa.

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

4.8     Undesirable effects

 

Data from large clinical trials were used to determine the frequency of adverse reactions.

The following convention has been used for the classification of frequencies: Very common 1/10; Common 1/100 to <1/10; Uncommon 1/1000 to <1/100; Rare 1/10,000 to <1/1000; Very rare <1/10,000.

 

Respiratory, thoracic and mediastinal disorders

 

 

Very common

Epistaxis

Common

Nasal ulceration

 

Epistaxis was generally mild to moderate in intensity. In adults and adolescents, the incidence of epistaxis was higher in longer-term use (more than 6 weeks) than in short-term use (up to 6 weeks). In paediatric clinical studies of up to 12 weeks duration the incidence of epistaxis was similar between patients receiving fluticasone furoate and patients receiving placebo.

 

Systemic effects of nasal corticosteroids may occur, particularly when prescribed at high doses for prolonged periods.

 

 

Updated on 1 July 2009 PIL

Reasons for updating

  • Change to warnings or special precautions for use
  • Change to side-effects
  • Change to dosage and administration

Updated on 5 March 2008 PIL

Reasons for updating

  • New PIL for new product

Updated on 5 March 2008 SmPC

Reasons for updating

  • New SPC for new product

Legal category: Product subject to medical prescription which may be renewed (B)